Finally, the new monoclonal antibodies targeting IFN-α (sifalimumab) and IFNAR (anifrolumab), whose efficacy has recently been demonstrated in SLE patients, represent another promising option for IFNopathy patients [119,122,239,240]. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.